Chronic Hepatitis D
Bluejay Therapeutics’ brelovitug secures FDA breakthrough status for chronic HDV
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the company announced in a press release.
VIDEO: Bulevirtide plus PEG-IFN a-2a potentially ‘viable finite therapy’ for chronic HDV
In a Healio video exclusive, Anu Osinusi, MD, MPH, reports that combination bulevirtide 10 mg with pegylated interferon alfa-2a for chronic hepatitis D virus infection resulted in the highest rates of undetectable HDV RNA through 48 weeks.
Bulevirtide monotherapy safe, well-tolerated in chronic hepatitis D patients
LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.
VIDEO: Bulevirtide improves quality of life in chronic HDV
Bulevirtide improved quality of life measures among patients treated for chronic hepatitis D virus, Maria Buti, MD, PhD, of the Hospital Universiario Valle Hebron, told Healio Gastroenterology.